KRAS mutations can induce
non-response to anti EGFR
monoclonals (panitumumab, cetuximab) or EGFR-TK
inhibitors. Such mutations
Mutations of the intracellular portion of EGFR involving exons 17 to 21 (a.a. 712 to 979), and especially exon 19, in Non small Cell Lung Cancer, can facilitate efficacy of oral TK inhibitors (gefitinib and erlotinib)
* KRAS Kirsten rat sarcoma viral oncogen homolog
a.a. = amino acid, followed by its number
Mab 806 (Ludwig Institute)
is a monoclonal specially
built against this deleted
variant of EGFR. A peptide vaccine (CDX 110) is in clinical trials against this variant
